A Once-Daily Dose-Ranging Study of GSK189075 [remogliflozin etabonate] Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naive Subjects.

Trial Profile

A Once-Daily Dose-Ranging Study of GSK189075 [remogliflozin etabonate] Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naive Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Remogliflozin etabonate (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Actual start date changed from Sep 2007 to Aug 2007 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top